Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis
The Journal of Infectious Diseases · 15.04.2025 · 231 (4) · 1049-1059
DOI: 10.1093/infdis/jiae494 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 08.10.2024. Verfasst von Tian Yao und 23 weiteren Autor:innen. Beteiligte Einrichtung: First Hospital/First Clinical Medical College, Shanxi Medical University, Taiyuan, China. Hauptthemen laut MEDLINE: Renal Dialysis, Hepatitis B Vaccines, Hepatitis B, Immunogenicity, Vaccine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Science and Technology Major Project, Ministry of Science and Technology of China, Key Research and Development Project of Lvliang City.
Abstract (Originalsprache)
Background
Patients receiving hemodialysis represent a high-risk group for hepatitis B virus (HBV) infection. It is crucial to administer hepatitis B vaccination and stimulate higher and more sustained levels of hepatitis B surface antibodies (anti -HBs). Our aim is to enhance the immunogenicity and persistence by implementing high-dose and prolonged hepatitis B vaccine schedules in patients receiving hemodialysis.
Methods
We conducted this multicenter, randomized, parallel-controlled trial between July 2020 and February 2023 at 11 hospitals in Shanxi province, China. A total of 504 patients receiving hemodialysis were enrolled. All participants were randomly allocated in a ratio of 1:1:1 to receive recombinant HBV vaccine of 3 standard doses (20 μg) at 0, 1, and 6 months (IM20 × 3 group), 4 standard doses at 0, 1, 2, and 6 months (IM20 × 4 group), or 4 triple doses (60 μg) at 0, 1, 2, and 6 months (IM60 × 4 group).
Results
The vaccine-elicited antibody response peaked at month 7. The follow-up from month 7 to 30 revealed that response rates of anti-HBs decreased from 85.9% (134/156) to 33.0% (33/100) in IM20 × 3 group, from 92.5% (135/146) to 53.9% (56/104) in IM20 × 4 group, and from 95.4% (145/152) to 57.3% (55/96) in IM60 × 4 group. The duration of vaccine-induced response with 75% of patients maintained protective antibodies were 21.0 months in IM20 × 3 group, 25.7 months in IM20 × 4 group (vs IM20 × 3 group, P = .056), and 29.2 months in IM60 × 4 group (vs IM20 × 3 group, P = .034). All the adverse reactions were mild.
Conclusions
The triple-strength 4-dose hepatitis B vaccination regimens could enhance the immunogenicity and 2-year duration in patients receiving hemodialysis. Clinical Trials Registration. NCT03962881.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Hospital/First Clinical Medical College, Shanxi Medical University, Taiyuan, China.
- Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, China.
- School of Public Health, Shanxi Medical University, Taiyuan, China.
- Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan, China.
- Department of Nephrology, Linfen Central Hospital, Linfen, China.
- Department of Nephrology, Shanxi Fenyang Hospital, Fenyang, China.
Förderung
- National Science and Technology Major Project
- Ministry of Science and Technology of China
- Key Research and Development Project of Lvliang City
- Key Research and Development Plan of Science and Technology of Linfen City
- Fundamental Research Program of Shanxi Province
- Scientific and Technological Innovation Programs of Higher Education Institutions in Shanxi Province
Zitieren
APA
Yao, T., Li, Y., Zhang, Y., Sun, Y., Guo, Y., Wang, J., Song, X., Zhang, W., Wei, B., Bai, J., Wang, H., Yu, W., Wang, H., Jiao, L., Diao, Y., Liu, L., Shi, S., Yang, J., Ren, X., …, & Feng, Y. (2025). Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis. The Journal of Infectious Diseases, 231(4), 1049-1059. https://doi.org/10.1093/infdis/jiae494
Vancouver
Yao T, Li Y, Zhang Y, Sun Y, Guo Y, Wang J, et al. Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis. The Journal of Infectious Diseases. 2025;231(4):1049-1059. doi:10.1093/infdis/jiae494
BibTeX
@article{Yao2025,
author = {Yao, Tian and Li, Yandi and Zhang, Yidan and Sun, Yangle and Guo, Yana and Wang, Jianmin and Song, Xiaohui and Zhang, Wei and Wei, Baozhu and Bai, Jingen and Wang, Hui and Yu, Weimin and Wang, Huiyuan and Jiao, Lu and Diao, Yinqiang and Liu, Liming and Shi, Shuaishuai and Yang, Jie and Ren, Xiaojun and Liu, Wenyuan and Fang, Jingai and Liang, Xiaofeng and Wang, Suping and Feng, Yongliang},
title = {Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {231},
number = {4},
pages = {1049--1059},
doi = {10.1093/infdis/jiae494}
}
EUVIMED